 Laurie Gaspar
Concepts (495)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 100 | 2022 | 975 | 8.160 |
Why?
| | Lung Neoplasms | 91 | 2023 | 2172 | 6.250 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 54 | 2022 | 995 | 4.920 |
Why?
| | Radiosurgery | 44 | 2022 | 294 | 4.770 |
Why?
| | Cranial Irradiation | 20 | 2022 | 63 | 3.250 |
Why?
| | Small Cell Lung Carcinoma | 11 | 2023 | 70 | 3.140 |
Why?
| | Combined Modality Therapy | 62 | 2022 | 1188 | 1.460 |
Why?
| | Radiation Pneumonitis | 5 | 2021 | 25 | 1.460 |
Why?
| | Radiotherapy, Intensity-Modulated | 9 | 2018 | 128 | 1.410 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 30 | 2023 | 1401 | 1.410 |
Why?
| | Carcinoma, Small Cell | 8 | 2007 | 159 | 1.340 |
Why?
| | Practice Guidelines as Topic | 14 | 2021 | 1524 | 1.330 |
Why?
| | Neoplasm Staging | 39 | 2020 | 1216 | 1.290 |
Why?
| | Radiotherapy Dosage | 39 | 2023 | 245 | 1.240 |
Why?
| | Chemoradiotherapy | 8 | 2020 | 196 | 1.200 |
Why?
| | Brachytherapy | 12 | 2017 | 94 | 1.120 |
Why?
| | Glioblastoma | 18 | 2016 | 252 | 1.090 |
Why?
| | Neoplasm Recurrence, Local | 21 | 2017 | 845 | 1.080 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 11 | 2021 | 124 | 1.060 |
Why?
| | Radiation Oncology | 12 | 2022 | 73 | 1.020 |
Why?
| | Liver Neoplasms | 8 | 2009 | 452 | 0.970 |
Why?
| | Glioma | 15 | 2015 | 293 | 0.910 |
Why?
| | Adenocarcinoma | 13 | 2022 | 818 | 0.880 |
Why?
| | Aged | 102 | 2020 | 20243 | 0.880 |
Why?
| | Esophageal Neoplasms | 9 | 2008 | 237 | 0.880 |
Why?
| | Humans | 222 | 2023 | 117481 | 0.840 |
Why?
| | Prognosis | 45 | 2022 | 3540 | 0.820 |
Why?
| | Survival Rate | 31 | 2018 | 1807 | 0.810 |
Why?
| | Middle Aged | 118 | 2020 | 28654 | 0.810 |
Why?
| | Radiotherapy, Conformal | 8 | 2017 | 67 | 0.780 |
Why?
| | Clinical Trials as Topic | 18 | 2018 | 998 | 0.760 |
Why?
| | Radiotherapy, Adjuvant | 16 | 2022 | 186 | 0.750 |
Why?
| | Radiotherapy | 14 | 2017 | 191 | 0.740 |
Why?
| | Neurosurgeons | 1 | 2019 | 12 | 0.740 |
Why?
| | Dacarbazine | 9 | 2016 | 105 | 0.730 |
Why?
| | Four-Dimensional Computed Tomography | 6 | 2021 | 27 | 0.700 |
Why?
| | Evidence-Based Medicine | 10 | 2021 | 724 | 0.690 |
Why?
| | Oncologists | 1 | 2018 | 28 | 0.660 |
Why?
| | Clinical Decision-Making | 3 | 2021 | 286 | 0.630 |
Why?
| | Male | 128 | 2022 | 60409 | 0.630 |
Why?
| | Patient Selection | 10 | 2019 | 698 | 0.630 |
Why?
| | Aged, 80 and over | 45 | 2020 | 6794 | 0.620 |
Why?
| | Cisplatin | 18 | 2021 | 270 | 0.620 |
Why?
| | Female | 131 | 2020 | 63228 | 0.620 |
Why?
| | Carcinoma, Squamous Cell | 10 | 2017 | 597 | 0.600 |
Why?
| | Antineoplastic Agents, Alkylating | 8 | 2016 | 65 | 0.590 |
Why?
| | Physician's Role | 1 | 2018 | 214 | 0.580 |
Why?
| | Antineoplastic Agents | 20 | 2017 | 2015 | 0.570 |
Why?
| | Induction Chemotherapy | 2 | 2013 | 56 | 0.550 |
Why?
| | Adult | 90 | 2020 | 32104 | 0.550 |
Why?
| | Treatment Outcome | 36 | 2021 | 9333 | 0.500 |
Why?
| | Receptor Protein-Tyrosine Kinases | 5 | 2017 | 267 | 0.490 |
Why?
| | Survival Analysis | 24 | 2020 | 1359 | 0.480 |
Why?
| | Physician-Patient Relations | 1 | 2018 | 506 | 0.480 |
Why?
| | Etoposide | 12 | 2021 | 160 | 0.470 |
Why?
| | Retrospective Studies | 40 | 2022 | 12318 | 0.450 |
Why?
| | Pro-Opiomelanocortin | 7 | 1989 | 23 | 0.440 |
Why?
| | Pneumonectomy | 2 | 2015 | 121 | 0.440 |
Why?
| | Astrocytoma | 9 | 2014 | 108 | 0.420 |
Why?
| | Medical Oncology | 7 | 2021 | 219 | 0.380 |
Why?
| | Melanoma | 5 | 2018 | 695 | 0.380 |
Why?
| | Whole-Body Irradiation | 1 | 2009 | 77 | 0.380 |
Why?
| | Chemotherapy, Adjuvant | 12 | 2017 | 341 | 0.370 |
Why?
| | Societies, Medical | 7 | 2021 | 754 | 0.370 |
Why?
| | Pulmonary Ventilation | 4 | 2021 | 73 | 0.370 |
Why?
| | Protein Kinase Inhibitors | 4 | 2021 | 862 | 0.370 |
Why?
| | Guidelines as Topic | 2 | 2020 | 282 | 0.370 |
Why?
| | Karnofsky Performance Status | 11 | 2020 | 39 | 0.370 |
Why?
| | Guideline Adherence | 4 | 2018 | 538 | 0.360 |
Why?
| | ErbB Receptors | 8 | 2022 | 568 | 0.360 |
Why?
| | Breast Neoplasms | 9 | 2020 | 1926 | 0.360 |
Why?
| | Dose-Response Relationship, Radiation | 11 | 2019 | 129 | 0.350 |
Why?
| | Lung | 9 | 2021 | 3641 | 0.350 |
Why?
| | Quinazolines | 6 | 2014 | 246 | 0.340 |
Why?
| | Iodine Radioisotopes | 6 | 2006 | 124 | 0.340 |
Why?
| | Re-Irradiation | 2 | 2018 | 8 | 0.330 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2007 | 29 | 0.330 |
Why?
| | Neoplasm Metastasis | 8 | 2019 | 593 | 0.330 |
Why?
| | Disease Progression | 13 | 2018 | 2542 | 0.330 |
Why?
| | Radiopharmaceuticals | 5 | 2014 | 170 | 0.320 |
Why?
| | Anticonvulsants | 2 | 2019 | 188 | 0.310 |
Why?
| | Follow-Up Studies | 22 | 2018 | 4914 | 0.310 |
Why?
| | Tumor Burden | 9 | 2017 | 283 | 0.310 |
Why?
| | Biomarkers, Tumor | 6 | 2021 | 1048 | 0.300 |
Why?
| | Prospective Studies | 22 | 2018 | 6420 | 0.290 |
Why?
| | Tomography, X-Ray Computed | 10 | 2018 | 2463 | 0.290 |
Why?
| | Paclitaxel | 5 | 2011 | 197 | 0.290 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2017 | 195 | 0.280 |
Why?
| | Carcinoma, Hepatocellular | 2 | 2005 | 184 | 0.280 |
Why?
| | Spinal Cord | 4 | 2018 | 400 | 0.270 |
Why?
| | Steroids | 2 | 2019 | 142 | 0.260 |
Why?
| | Taxoids | 5 | 2015 | 95 | 0.260 |
Why?
| | Carcinoma | 1 | 2006 | 205 | 0.260 |
Why?
| | Lymphatic Metastasis | 3 | 2017 | 302 | 0.250 |
Why?
| | Magnetic Resonance Imaging | 9 | 2019 | 3213 | 0.250 |
Why?
| | Central Nervous System | 2 | 2017 | 262 | 0.250 |
Why?
| | Carcinoma, Renal Cell | 3 | 2018 | 173 | 0.250 |
Why?
| | Gastrointestinal Neoplasms | 3 | 2019 | 57 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 7 | 2021 | 1205 | 0.240 |
Why?
| | Neoplasms | 6 | 2020 | 2137 | 0.220 |
Why?
| | Positron Emission Tomography Computed Tomography | 2 | 2020 | 66 | 0.220 |
Why?
| | Necrosis | 3 | 2019 | 232 | 0.220 |
Why?
| | Medical Illustration | 2 | 2012 | 10 | 0.220 |
Why?
| | Radiography | 8 | 2014 | 860 | 0.220 |
Why?
| | Organs at Risk | 2 | 2012 | 30 | 0.220 |
Why?
| | Brachial Plexus | 2 | 2012 | 28 | 0.220 |
Why?
| | Ribs | 2 | 2012 | 35 | 0.220 |
Why?
| | Esophagectomy | 1 | 2002 | 70 | 0.210 |
Why?
| | Professional Staff Committees | 4 | 2001 | 15 | 0.210 |
Why?
| | Oligodendroglioma | 4 | 2014 | 14 | 0.210 |
Why?
| | Testicular Neoplasms | 1 | 2022 | 84 | 0.210 |
Why?
| | Mutation | 4 | 2021 | 3406 | 0.200 |
Why?
| | Research Design | 7 | 2018 | 969 | 0.190 |
Why?
| | Thymus Neoplasms | 2 | 2017 | 21 | 0.190 |
Why?
| | Thymoma | 2 | 2017 | 32 | 0.190 |
Why?
| | Proportional Hazards Models | 8 | 2020 | 1200 | 0.190 |
Why?
| | Peptide Fragments | 4 | 1989 | 718 | 0.190 |
Why?
| | Consolidation Chemotherapy | 1 | 2019 | 12 | 0.190 |
Why?
| | Esophagus | 2 | 2012 | 239 | 0.190 |
Why?
| | Meningeal Neoplasms | 3 | 2017 | 78 | 0.180 |
Why?
| | Maximum Tolerated Dose | 6 | 2010 | 189 | 0.180 |
Why?
| | Metalloporphyrins | 3 | 2011 | 109 | 0.180 |
Why?
| | Congresses as Topic | 2 | 2019 | 205 | 0.180 |
Why?
| | Radiation Injuries | 5 | 2015 | 137 | 0.180 |
Why?
| | Watchful Waiting | 1 | 2019 | 57 | 0.180 |
Why?
| | Expert Testimony | 1 | 2019 | 55 | 0.180 |
Why?
| | Aquaporin 4 | 1 | 2019 | 79 | 0.180 |
Why?
| | Time Factors | 10 | 2019 | 6905 | 0.180 |
Why?
| | Intracranial Arteriovenous Malformations | 2 | 1995 | 23 | 0.170 |
Why?
| | Gray Matter | 1 | 2019 | 68 | 0.170 |
Why?
| | CTLA-4 Antigen | 1 | 2018 | 78 | 0.170 |
Why?
| | Spinal Neoplasms | 1 | 2018 | 28 | 0.170 |
Why?
| | Cognition | 4 | 2013 | 1019 | 0.170 |
Why?
| | Quality of Life | 5 | 2013 | 2351 | 0.170 |
Why?
| | Carboplatin | 4 | 2011 | 142 | 0.160 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 60 | 0.160 |
Why?
| | Endpoint Determination | 1 | 2018 | 67 | 0.160 |
Why?
| | Kidney Neoplasms | 3 | 2018 | 342 | 0.160 |
Why?
| | Pituitary Neoplasms | 5 | 1994 | 154 | 0.160 |
Why?
| | Treatment Failure | 5 | 2014 | 339 | 0.160 |
Why?
| | Professional Competence | 1 | 2018 | 100 | 0.160 |
Why?
| | Receptor, ErbB-2 | 5 | 2020 | 318 | 0.160 |
Why?
| | Mortality | 1 | 2019 | 317 | 0.160 |
Why?
| | Genes, ras | 1 | 2017 | 97 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 153 | 0.160 |
Why?
| | Decision Trees | 1 | 1997 | 88 | 0.160 |
Why?
| | Triazines | 2 | 2009 | 40 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 63 | 0.160 |
Why?
| | Fluorouracil | 6 | 2004 | 150 | 0.150 |
Why?
| | Interdisciplinary Communication | 1 | 2018 | 201 | 0.150 |
Why?
| | Salvage Therapy | 4 | 2017 | 136 | 0.150 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 188 | 0.150 |
Why?
| | Hemangioma, Cavernous | 2 | 1993 | 17 | 0.150 |
Why?
| | Cohort Studies | 7 | 2019 | 5106 | 0.150 |
Why?
| | Brain | 5 | 2019 | 2697 | 0.150 |
Why?
| | Pulmonary Atelectasis | 1 | 2015 | 15 | 0.150 |
Why?
| | Patient Preference | 1 | 2018 | 174 | 0.140 |
Why?
| | Antibodies | 1 | 2018 | 405 | 0.140 |
Why?
| | Accreditation | 2 | 2013 | 96 | 0.140 |
Why?
| | United States | 13 | 2022 | 12756 | 0.140 |
Why?
| | Radiation-Sensitizing Agents | 5 | 2009 | 37 | 0.140 |
Why?
| | Age Factors | 8 | 2017 | 3221 | 0.140 |
Why?
| | Postoperative Care | 1 | 2017 | 229 | 0.140 |
Why?
| | Adrenal Cortex Hormones | 1 | 2019 | 517 | 0.140 |
Why?
| | Central Nervous System Neoplasms | 1 | 2017 | 126 | 0.140 |
Why?
| | Medically Underserved Area | 1 | 2016 | 99 | 0.140 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 119 | 0.130 |
Why?
| | Antineoplastic Agents, Phytogenic | 2 | 2006 | 194 | 0.130 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2017 | 159 | 0.130 |
Why?
| | Carmustine | 7 | 2010 | 51 | 0.130 |
Why?
| | Camptothecin | 2 | 2011 | 95 | 0.130 |
Why?
| | Perfusion Imaging | 1 | 2014 | 52 | 0.130 |
Why?
| | Cerebellar Neoplasms | 2 | 1996 | 126 | 0.130 |
Why?
| | Fibrosarcoma | 1 | 1993 | 22 | 0.130 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2014 | 20 | 0.130 |
Why?
| | Adolescent | 22 | 2017 | 18875 | 0.130 |
Why?
| | Medulloblastoma | 2 | 1996 | 171 | 0.130 |
Why?
| | Risk Assessment | 3 | 2021 | 3206 | 0.120 |
Why?
| | Nelson Syndrome | 4 | 1987 | 4 | 0.120 |
Why?
| | Contraindications | 2 | 2008 | 93 | 0.120 |
Why?
| | Receptors, Progesterone | 4 | 2020 | 324 | 0.120 |
Why?
| | Pyrazoles | 2 | 2014 | 401 | 0.120 |
Why?
| | Analysis of Variance | 5 | 2014 | 1454 | 0.120 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1193 | 0.120 |
Why?
| | Respiratory Function Tests | 1 | 2015 | 595 | 0.120 |
Why?
| | Pyridines | 2 | 2014 | 471 | 0.120 |
Why?
| | Disease-Free Survival | 6 | 2014 | 676 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 5 | 2019 | 897 | 0.120 |
Why?
| | beta-Endorphin | 3 | 1989 | 7 | 0.120 |
Why?
| | Pancreatic Neoplasms | 1 | 2000 | 753 | 0.110 |
Why?
| | Radiotherapy, High-Energy | 4 | 2000 | 12 | 0.110 |
Why?
| | Particle Accelerators | 1 | 1991 | 9 | 0.110 |
Why?
| | Bone Neoplasms | 3 | 2007 | 204 | 0.110 |
Why?
| | Adrenocorticotropic Hormone | 3 | 1989 | 160 | 0.110 |
Why?
| | Radiation Protection | 2 | 2009 | 37 | 0.110 |
Why?
| | Young Adult | 8 | 2017 | 11069 | 0.110 |
Why?
| | Hyperthermia, Induced | 1 | 1992 | 70 | 0.100 |
Why?
| | Databases, Factual | 5 | 2017 | 1145 | 0.100 |
Why?
| | Forced Expiratory Volume | 2 | 2015 | 597 | 0.100 |
Why?
| | Quality Assurance, Health Care | 3 | 2009 | 355 | 0.100 |
Why?
| | Bevacizumab | 3 | 2015 | 122 | 0.100 |
Why?
| | Technology, Radiologic | 1 | 2010 | 6 | 0.100 |
Why?
| | Radiotherapy, Computer-Assisted | 1 | 2010 | 13 | 0.100 |
Why?
| | MEDLINE | 1 | 2009 | 26 | 0.100 |
Why?
| | Spine | 1 | 1991 | 137 | 0.100 |
Why?
| | Clinical Trials, Phase II as Topic | 2 | 2002 | 61 | 0.100 |
Why?
| | Neurosurgery | 1 | 2009 | 22 | 0.100 |
Why?
| | Adenoma | 4 | 1994 | 184 | 0.100 |
Why?
| | Palliative Care | 5 | 2018 | 638 | 0.090 |
Why?
| | Adrenal Medulla | 1 | 1989 | 8 | 0.090 |
Why?
| | Risk Factors | 7 | 2021 | 9124 | 0.090 |
Why?
| | Neurotensin | 1 | 1989 | 12 | 0.090 |
Why?
| | Drug Therapy | 1 | 2009 | 74 | 0.090 |
Why?
| | Piperidines | 1 | 2010 | 174 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2877 | 0.090 |
Why?
| | Multivariate Analysis | 6 | 2020 | 1585 | 0.090 |
Why?
| | Ependymoma | 2 | 2009 | 163 | 0.090 |
Why?
| | Fractures, Spontaneous | 1 | 1988 | 15 | 0.090 |
Why?
| | Meta-Analysis as Topic | 1 | 2009 | 151 | 0.090 |
Why?
| | Catheter Ablation | 1 | 2012 | 341 | 0.090 |
Why?
| | Education, Medical, Graduate | 1 | 2013 | 418 | 0.090 |
Why?
| | Esophageal Fistula | 2 | 2000 | 20 | 0.090 |
Why?
| | Pheochromocytoma | 1 | 1989 | 52 | 0.090 |
Why?
| | Liver | 2 | 2008 | 1852 | 0.090 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 137 | 0.090 |
Why?
| | Equipment Failure Analysis | 1 | 2009 | 135 | 0.090 |
Why?
| | Respiratory Mechanics | 1 | 2008 | 79 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 2 | 2010 | 556 | 0.090 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1989 | 78 | 0.090 |
Why?
| | Humeral Fractures | 1 | 1988 | 53 | 0.090 |
Why?
| | Femoral Fractures | 1 | 1988 | 75 | 0.090 |
Why?
| | Craniopharyngioma | 1 | 2009 | 71 | 0.090 |
Why?
| | Lymph Node Excision | 1 | 2009 | 154 | 0.090 |
Why?
| | Positron-Emission Tomography | 2 | 2008 | 273 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2018 | 4847 | 0.080 |
Why?
| | Chromatography, Gel | 4 | 1989 | 132 | 0.080 |
Why?
| | Kidney | 2 | 2005 | 1236 | 0.080 |
Why?
| | Radioimmunoassay | 4 | 1989 | 179 | 0.080 |
Why?
| | Uterine Cervical Neoplasms | 1 | 1989 | 205 | 0.080 |
Why?
| | Statistics, Nonparametric | 2 | 2018 | 444 | 0.080 |
Why?
| | Seizures | 1 | 2009 | 344 | 0.080 |
Why?
| | Biomedical Research | 2 | 2009 | 598 | 0.070 |
Why?
| | Clinical Competence | 1 | 2013 | 946 | 0.070 |
Why?
| | Whole Body Imaging | 1 | 2006 | 24 | 0.070 |
Why?
| | Neoplasm Grading | 2 | 2020 | 253 | 0.070 |
Why?
| | Vascular Diseases | 1 | 2009 | 238 | 0.070 |
Why?
| | Hepatitis B, Chronic | 1 | 2005 | 18 | 0.070 |
Why?
| | Genetic Markers | 2 | 2017 | 349 | 0.070 |
Why?
| | Hemoglobins | 1 | 2007 | 282 | 0.070 |
Why?
| | Strontium Radioisotopes | 2 | 2006 | 3 | 0.070 |
Why?
| | Diagnostic Imaging | 3 | 2009 | 292 | 0.070 |
Why?
| | Antiemetics | 1 | 2005 | 33 | 0.070 |
Why?
| | Immunotherapy | 2 | 2022 | 476 | 0.070 |
Why?
| | Databases as Topic | 1 | 2005 | 60 | 0.070 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 780 | 0.070 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2015 | 1418 | 0.070 |
Why?
| | Linear Models | 3 | 2017 | 873 | 0.070 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 507 | 0.070 |
Why?
| | Anticoagulants | 1 | 2009 | 542 | 0.070 |
Why?
| | Physicians | 1 | 2013 | 771 | 0.070 |
Why?
| | Gene Rearrangement | 2 | 2018 | 158 | 0.070 |
Why?
| | Feasibility Studies | 3 | 2011 | 766 | 0.070 |
Why?
| | Pituitary Hormones | 1 | 1984 | 17 | 0.070 |
Why?
| | Peptides | 3 | 1985 | 874 | 0.070 |
Why?
| | Consensus | 2 | 2021 | 506 | 0.070 |
Why?
| | Delivery of Health Care | 1 | 2012 | 815 | 0.070 |
Why?
| | Body Fluids | 1 | 1985 | 66 | 0.070 |
Why?
| | Dexamethasone | 3 | 2012 | 304 | 0.070 |
Why?
| | Organ Size | 1 | 2005 | 492 | 0.070 |
Why?
| | Retreatment | 3 | 2012 | 70 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1228 | 0.060 |
Why?
| | Age Distribution | 1 | 2005 | 382 | 0.060 |
Why?
| | Sex Distribution | 1 | 2005 | 390 | 0.060 |
Why?
| | Liver Cirrhosis | 1 | 2005 | 223 | 0.060 |
Why?
| | Erlotinib Hydrochloride | 2 | 2014 | 69 | 0.060 |
Why?
| | Cognition Disorders | 2 | 2010 | 580 | 0.060 |
Why?
| | Hepatitis C, Chronic | 1 | 2005 | 152 | 0.060 |
Why?
| | Propionates | 1 | 2003 | 34 | 0.060 |
Why?
| | Regression Analysis | 2 | 2017 | 1073 | 0.060 |
Why?
| | Preoperative Care | 1 | 2005 | 323 | 0.060 |
Why?
| | Internship and Residency | 1 | 2013 | 1024 | 0.060 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2006 | 234 | 0.060 |
Why?
| | Aniline Compounds | 1 | 2003 | 67 | 0.060 |
Why?
| | Chromatography, Affinity | 3 | 1989 | 92 | 0.060 |
Why?
| | Societies | 1 | 2022 | 42 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2004 | 83 | 0.060 |
Why?
| | Pterygium | 1 | 2000 | 4 | 0.050 |
Why?
| | Organizational Objectives | 4 | 2001 | 71 | 0.050 |
Why?
| | Algorithms | 2 | 2017 | 1549 | 0.050 |
Why?
| | B7-H1 Antigen | 1 | 2022 | 135 | 0.050 |
Why?
| | Ontario | 2 | 2017 | 56 | 0.050 |
Why?
| | Esophagoscopy | 1 | 2002 | 192 | 0.050 |
Why?
| | Vincristine | 2 | 2010 | 106 | 0.050 |
Why?
| | Reproducibility of Results | 2 | 2015 | 2942 | 0.050 |
Why?
| | Neurologic Examination | 1 | 2000 | 125 | 0.050 |
Why?
| | BRCA1 Protein | 1 | 2020 | 53 | 0.050 |
Why?
| | Carcinoma, Bronchogenic | 1 | 1999 | 16 | 0.050 |
Why?
| | Spinal Cord Neoplasms | 1 | 1999 | 35 | 0.050 |
Why?
| | Carcinoma, Large Cell | 1 | 1999 | 15 | 0.050 |
Why?
| | Receptors, Estrogen | 2 | 2013 | 387 | 0.050 |
Why?
| | Reoperation | 2 | 2012 | 553 | 0.040 |
Why?
| | Medical Records | 2 | 2010 | 176 | 0.040 |
Why?
| | Neuropsychological Tests | 3 | 2013 | 1115 | 0.040 |
Why?
| | Liver Transplantation | 1 | 2005 | 798 | 0.040 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2001 | 194 | 0.040 |
Why?
| | Estrogens | 1 | 2020 | 306 | 0.040 |
Why?
| | Child, Preschool | 7 | 2009 | 9699 | 0.040 |
Why?
| | Thoracic Vertebrae | 1 | 2018 | 72 | 0.040 |
Why?
| | Iridium Radioisotopes | 1 | 1997 | 6 | 0.040 |
Why?
| | Aziridines | 2 | 1994 | 4 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2017 | 70 | 0.040 |
Why?
| | Precision Medicine | 1 | 2020 | 291 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 1997 | 53 | 0.040 |
Why?
| | Colorado | 3 | 2014 | 4401 | 0.040 |
Why?
| | Molecular Weight | 2 | 1989 | 350 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2017 | 193 | 0.040 |
Why?
| | Neutropenia | 2 | 2009 | 128 | 0.040 |
Why?
| | Benzoquinones | 2 | 1994 | 46 | 0.040 |
Why?
| | Propensity Score | 1 | 2018 | 251 | 0.040 |
Why?
| | Esophagitis | 2 | 2009 | 67 | 0.040 |
Why?
| | Skin Neoplasms | 2 | 2017 | 808 | 0.040 |
Why?
| | Supratentorial Neoplasms | 1 | 1996 | 19 | 0.040 |
Why?
| | Memory Disorders | 2 | 2010 | 181 | 0.040 |
Why?
| | Respiration | 1 | 2017 | 196 | 0.040 |
Why?
| | Meningioma | 1 | 1997 | 69 | 0.040 |
Why?
| | Estrogen Receptor alpha | 1 | 2017 | 117 | 0.040 |
Why?
| | Odds Ratio | 1 | 1999 | 1038 | 0.040 |
Why?
| | Heart | 1 | 2020 | 661 | 0.040 |
Why?
| | Pilot Projects | 3 | 2015 | 1438 | 0.040 |
Why?
| | Sex Factors | 2 | 2014 | 1921 | 0.040 |
Why?
| | Cerebral Angiography | 1 | 1995 | 90 | 0.040 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2014 | 6 | 0.030 |
Why?
| | Ventilation-Perfusion Ratio | 1 | 2014 | 14 | 0.030 |
Why?
| | Nuclear Medicine | 1 | 2014 | 7 | 0.030 |
Why?
| | Marital Status | 1 | 2014 | 53 | 0.030 |
Why?
| | Child | 9 | 2009 | 18613 | 0.030 |
Why?
| | Forecasting | 3 | 2001 | 371 | 0.030 |
Why?
| | Vital Capacity | 1 | 2015 | 277 | 0.030 |
Why?
| | Texas | 1 | 2014 | 178 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 1000 | 0.030 |
Why?
| | Radioisotope Teletherapy | 1 | 1993 | 2 | 0.030 |
Why?
| | Patient Safety | 1 | 2017 | 310 | 0.030 |
Why?
| | Cobalt Radioisotopes | 1 | 1993 | 6 | 0.030 |
Why?
| | Developing Countries | 1 | 2016 | 251 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 1997 | 256 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 375 | 0.030 |
Why?
| | SEER Program | 1 | 2014 | 198 | 0.030 |
Why?
| | Vimentin | 1 | 1993 | 62 | 0.030 |
Why?
| | Radiodermatitis | 1 | 1993 | 7 | 0.030 |
Why?
| | Spatial Analysis | 1 | 2013 | 29 | 0.030 |
Why?
| | Radiometry | 1 | 2013 | 45 | 0.030 |
Why?
| | Scalp | 1 | 1993 | 26 | 0.030 |
Why?
| | Observer Variation | 1 | 2014 | 326 | 0.030 |
Why?
| | Monte Carlo Method | 1 | 2013 | 156 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2001 | 977 | 0.030 |
Why?
| | Time | 1 | 2013 | 87 | 0.030 |
Why?
| | Mitosis | 1 | 1993 | 169 | 0.030 |
Why?
| | Ascorbic Acid | 1 | 1993 | 112 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2013 | 146 | 0.030 |
Why?
| | Medical Errors | 1 | 2013 | 99 | 0.030 |
Why?
| | Cerebral Cortex | 1 | 1996 | 491 | 0.030 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2016 | 442 | 0.030 |
Why?
| | Remission Induction | 2 | 2008 | 264 | 0.030 |
Why?
| | International Agencies | 1 | 2011 | 34 | 0.030 |
Why?
| | Disease Management | 1 | 2016 | 602 | 0.030 |
Why?
| | Electrons | 1 | 1991 | 73 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2011 | 30 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2015 | 1405 | 0.030 |
Why?
| | Bronchography | 1 | 2010 | 12 | 0.030 |
Why?
| | Fibrosis | 1 | 2013 | 458 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2665 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 2004 | 393 | 0.030 |
Why?
| | Radiology | 1 | 2014 | 195 | 0.030 |
Why?
| | Lomustine | 1 | 1990 | 12 | 0.030 |
Why?
| | Procarbazine | 1 | 1990 | 10 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1895 | 0.020 |
Why?
| | Cell Nucleus | 1 | 1993 | 588 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2010 | 93 | 0.020 |
Why?
| | Physics | 1 | 2010 | 20 | 0.020 |
Why?
| | Selection Bias | 1 | 2009 | 36 | 0.020 |
Why?
| | Clinical Trials Data Monitoring Committees | 1 | 2009 | 5 | 0.020 |
Why?
| | Chromatin | 1 | 1993 | 435 | 0.020 |
Why?
| | Hypophysectomy | 1 | 1989 | 17 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 154 | 0.020 |
Why?
| | Platinum | 1 | 2009 | 38 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2434 | 0.020 |
Why?
| | Incidence | 1 | 2016 | 2505 | 0.020 |
Why?
| | Adrenal Cortex | 1 | 1989 | 35 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1993 | 1755 | 0.020 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2008 | 11 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 1988 | 11 | 0.020 |
Why?
| | Bronchi | 1 | 2010 | 249 | 0.020 |
Why?
| | Certification | 1 | 2010 | 114 | 0.020 |
Why?
| | Liver Regeneration | 1 | 2008 | 31 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 1777 | 0.020 |
Why?
| | beta-Lipotropin | 2 | 1985 | 2 | 0.020 |
Why?
| | Endorphins | 2 | 1985 | 19 | 0.020 |
Why?
| | Smoking | 1 | 2017 | 1654 | 0.020 |
Why?
| | Prostheses and Implants | 1 | 2010 | 161 | 0.020 |
Why?
| | Infant | 4 | 1999 | 8243 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2012 | 470 | 0.020 |
Why?
| | Fracture Fixation, Intramedullary | 1 | 1988 | 58 | 0.020 |
Why?
| | Motion | 1 | 2008 | 98 | 0.020 |
Why?
| | Administration, Oral | 1 | 2010 | 786 | 0.020 |
Why?
| | Mental Status Schedule | 1 | 2007 | 38 | 0.020 |
Why?
| | Epinephrine | 1 | 1989 | 183 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 2008 | 112 | 0.020 |
Why?
| | International Cooperation | 1 | 2008 | 181 | 0.020 |
Why?
| | Reference Values | 1 | 1989 | 836 | 0.020 |
Why?
| | Bleomycin | 1 | 2009 | 211 | 0.020 |
Why?
| | Creatinine | 1 | 1989 | 472 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1969 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2204 | 0.020 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1989 | 507 | 0.020 |
Why?
| | Hydrocephalus | 1 | 1987 | 69 | 0.020 |
Why?
| | California | 1 | 2008 | 385 | 0.020 |
Why?
| | Southwestern United States | 1 | 2006 | 94 | 0.020 |
Why?
| | Methadone | 1 | 1987 | 75 | 0.020 |
Why?
| | DNA Repair | 1 | 2008 | 189 | 0.020 |
Why?
| | Chromium Compounds | 1 | 2006 | 2 | 0.020 |
Why?
| | Sodium Iodide | 1 | 2006 | 4 | 0.020 |
Why?
| | Polycythemia Vera | 1 | 2006 | 13 | 0.020 |
Why?
| | Pleural Effusion, Malignant | 1 | 2006 | 16 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2008 | 289 | 0.020 |
Why?
| | Yttrium Radioisotopes | 1 | 2006 | 20 | 0.020 |
Why?
| | Hyperthyroidism | 1 | 2006 | 28 | 0.020 |
Why?
| | Patient Isolation | 1 | 2006 | 18 | 0.020 |
Why?
| | Ascites | 1 | 2006 | 35 | 0.020 |
Why?
| | Glucocorticoids | 1 | 2010 | 555 | 0.020 |
Why?
| | DNA Damage | 1 | 2008 | 372 | 0.020 |
Why?
| | Organometallic Compounds | 1 | 2006 | 91 | 0.020 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2006 | 84 | 0.020 |
Why?
| | Chromatography | 1 | 1985 | 28 | 0.020 |
Why?
| | Organophosphorus Compounds | 1 | 2006 | 82 | 0.020 |
Why?
| | Concanavalin A | 1 | 1985 | 81 | 0.020 |
Why?
| | ACTH Syndrome, Ectopic | 1 | 1984 | 2 | 0.020 |
Why?
| | Occipital Lobe | 1 | 2004 | 22 | 0.020 |
Why?
| | Phosphates | 1 | 2006 | 176 | 0.020 |
Why?
| | Genomics | 1 | 2009 | 533 | 0.020 |
Why?
| | Biotransformation | 1 | 1984 | 57 | 0.020 |
Why?
| | Carbohydrate Metabolism | 1 | 1984 | 52 | 0.020 |
Why?
| | Brain Edema | 1 | 2004 | 61 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 2010 | 719 | 0.020 |
Why?
| | Recurrence | 2 | 2000 | 1007 | 0.020 |
Why?
| | Arginine Vasopressin | 1 | 1984 | 73 | 0.020 |
Why?
| | Thrombocytopenia | 1 | 2006 | 188 | 0.020 |
Why?
| | Vomiting | 1 | 2004 | 124 | 0.020 |
Why?
| | Bipolar Disorder | 1 | 1985 | 207 | 0.020 |
Why?
| | Oils | 1 | 1983 | 20 | 0.020 |
Why?
| | Corticotropin-Releasing Hormone | 1 | 1984 | 98 | 0.020 |
Why?
| | Thyroid Neoplasms | 1 | 2006 | 240 | 0.010 |
Why?
| | Motor Skills | 1 | 2004 | 94 | 0.010 |
Why?
| | Immunologic Factors | 1 | 2003 | 229 | 0.010 |
Why?
| | Opioid-Related Disorders | 1 | 1987 | 355 | 0.010 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2001 | 84 | 0.010 |
Why?
| | Pain | 1 | 2006 | 797 | 0.010 |
Why?
| | Psychometrics | 1 | 2004 | 689 | 0.010 |
Why?
| | Postoperative Period | 1 | 2000 | 307 | 0.010 |
Why?
| | Thorax | 1 | 1999 | 50 | 0.010 |
Why?
| | Michigan | 1 | 1999 | 97 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2006 | 1266 | 0.010 |
Why?
| | Cysts | 1 | 1999 | 84 | 0.010 |
Why?
| | Bias | 1 | 1999 | 199 | 0.010 |
Why?
| | Apoptosis | 1 | 2008 | 2572 | 0.010 |
Why?
| | Meninges | 1 | 1997 | 34 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2007 | 4621 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1996 | 18 | 0.010 |
Why?
| | Mitomycin | 1 | 1996 | 26 | 0.010 |
Why?
| | Biopsy | 1 | 1999 | 1068 | 0.010 |
Why?
| | Autoantibodies | 1 | 1983 | 1290 | 0.010 |
Why?
| | Decision Making | 1 | 2001 | 806 | 0.010 |
Why?
| | Cause of Death | 1 | 1996 | 399 | 0.010 |
Why?
| | Solutions | 1 | 1993 | 157 | 0.010 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 1993 | 74 | 0.010 |
Why?
| | Cerebral Hemorrhage | 1 | 1993 | 89 | 0.010 |
Why?
| | Brain Injuries | 1 | 1976 | 471 | 0.010 |
Why?
| | Computer Simulation | 1 | 1995 | 922 | 0.010 |
Why?
| | Patient Compliance | 1 | 1994 | 588 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1989 | 208 | 0.010 |
Why?
| | Double-Blind Method | 1 | 1993 | 1690 | 0.010 |
Why?
| | Melanocyte-Stimulating Hormones | 1 | 1985 | 3 | 0.000 |
Why?
| | Anti-Bacterial Agents | 1 | 1976 | 1417 | 0.000 |
Why?
| | Lithium | 1 | 1985 | 37 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1996 | 2113 | 0.000 |
Why?
| | Brassica | 1 | 1983 | 6 | 0.000 |
Why?
| | Spain | 1 | 1983 | 40 | 0.000 |
Why?
| | Drug Synergism | 1 | 1984 | 349 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1983 | 95 | 0.000 |
Why?
| | Syndrome | 1 | 1983 | 351 | 0.000 |
Why?
| | In Vitro Techniques | 1 | 1984 | 1144 | 0.000 |
Why?
| | Sheep | 1 | 1984 | 747 | 0.000 |
Why?
| | Wound Infection | 1 | 1976 | 29 | 0.000 |
Why?
| | Skull | 1 | 1976 | 147 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1976 | 220 | 0.000 |
Why?
| | Animals | 1 | 1984 | 34332 | 0.000 |
Why?
|
|
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|